09:48 AM EST - Fennec Pharmaceuticals Inc. : Announced that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has received positive final draft guidance from National Institute for Health and Care Excellence (NICE) recommending PEDMARQSI for the prevention of cisplatin-induced hearing loss in patients (aged one month to 17 years) with localized, non-metastatic, solid tumors. Fennec Pharmaceuticals Inc.
shares T.FRX are trading unchanged at $8.46.
